Effects of Magnesium and Spinning Training on Echocardiographic, Inflammatory, and Aerobic Outcomes
2026年6月17日 更新者：Hikmet Kocaman、Karamanoğlu Mehmetbey University
Effects of Magnesium Supplementation and Spinning Training on Cardiac Function, Oxidative Stress, Inflammation, and Aerobic Capacity
Regular aerobic exercise may improve cardiorespiratory fitness while modulating systemic inflammation and oxidative stress. Spinning, as a structured indoor cycling modality, provides a practical aerobic exercise model with adjustable intensity and duration, but its effects on redox balance, inflammatory status, aerobic capacity, and cardiac functional parameters may vary according to individual recovery and nutritional status. Magnesium is an essential micronutrient involved in energy metabolism, muscle contraction-relaxation, ion regulation, and inflammatory and oxidative pathways; therefore, magnesium use may be relevant to exercise adaptation and recovery.
This study aims to evaluate the associations of magnesium use and spinning training with oxidative stress, inflammation, aerobic capacity, and cardiac parameters. In this context, biochemical markers related to oxidative/antioxidant status and inflammation, aerobic performance indicators, and echocardiographic cardiac function parameters will be assessed together. The study is expected to provide real-world evidence on whether magnesium use in individuals participating in spinning training is associated with more favorable redox, inflammatory, aerobic, and cardiac profiles.
調査の概要
状態
招待による登録
研究の種類
介入
入学 (推定)
48
段階
- 適用できない
連絡先と場所
このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。
研究場所
-
-
-
Karaman、トルコ（Türkiye）、70100
- Karamanoğlu Mehmetbey University, Faculty of Sport Sciences
-
-
参加基準
研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。
適格基準
就学可能な年齢
- 大人
健康ボランティアの受け入れ
はい
説明
Inclusion Criteria:
- Self-identified male participants
- Aged 18 to 30 years
- Physically active individuals
- Participants who are eligible to participate in a structured spinning training program
- Participants with available baseline and follow-up assessments for biochemical, aerobic capacity, and cardiac function parameters
Exclusion Criteria:
- Presence of any chronic systemic disease
- Acute infection during the study period
- Regular use of anti-inflammatory or antioxidant medications
- Use of antioxidant or ergogenic supplements other than magnesium
- Any cardiovascular, musculoskeletal, or neurological condition that may limit participation in spinning training
- Missing baseline or follow-up outcome data
研究計画
このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。
研究はどのように設計されていますか？
デザインの詳細
- 主な目的：基礎科学
- 割り当て：ランダム化
- 介入モデル：並列代入
- マスキング：独身
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
介入なし：Control group
Participants in this arm will not receive any exercise training, magnesium supplementation, or placebo intervention during the study period.
They will continue their usual daily routines and will undergo the same baseline and follow-up assessments as the intervention groups.
|
|
|
アクティブコンパレータ：Spinning Training Group
Participants in this arm will participate in a structured spinning training program during the study period.
No magnesium supplementation or placebo will be administered.
Baseline and follow-up assessments will include oxidative stress, inflammatory, aerobic capacity, and cardiac function parameters.
|
Participants will participate in a structured spinning training program during the study period.
The program will consist of supervised indoor cycling sessions performed at a planned frequency, duration, and intensity.
|
|
実験的：Spinning + Magnesium Group
Participants in this arm will participate in a structured spinning training program and receive magnesium supplementation during the study period.
Baseline and follow-up assessments will include oxidative stress, inflammatory, aerobic capacity, and cardiac function parameters.
|
Participants will participate in a structured spinning training program during the study period.
The program will consist of supervised indoor cycling sessions performed at a planned frequency, duration, and intensity.
Participants will receive oral magnesium supplementation during the study period in addition to the structured spinning training program.
|
この研究は何を測定していますか？
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Change in Maximal Oxygen Uptake (VO₂max)
時間枠：Baseline and 6 weeks
|
Maximal oxygen uptake (VO₂max, mL/kg/min) will be assessed using a graded exercise test.
The change in VO₂max from baseline to 6 weeks will be evaluated.
|
Baseline and 6 weeks
|
|
Change in Serum Magnesium Concentration
時間枠：Baseline and 6 weeks
|
Serum magnesium concentration (mg/dL) will be measured using standard laboratory methods.
The change in serum magnesium levels from baseline to 6 weeks will be evaluated.
|
Baseline and 6 weeks
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Change in Total Antioxidant Status (TAS)
時間枠：Baseline and 6 weeks
|
Serum total antioxidant status (TAS, mmol Trolox equivalent/L) will be measured using commercially available assay kits.
The change in TAS from baseline to 6 weeks will be evaluated.
|
Baseline and 6 weeks
|
|
Change in Total Oxidant Status (TOS)
時間枠：Baseline and 6 weeks
|
Serum total oxidant status (TOS, μmol H₂O₂ equivalent/L) will be measured using commercially available assay kits.
The change in TOS from baseline to 6 weeks will be evaluated.
|
Baseline and 6 weeks
|
|
Change in Paraoxonase-1 Activity (PON1)
時間枠：Baseline and 6 weeks
|
Serum paraoxonase-1 (PON1, U/L) activity will be determined using spectrophotometric methods.
The change in PON1 activity from baseline to 6 weeks will be evaluated.
|
Baseline and 6 weeks
|
|
Change in Arylesterase Activity (ARE)
時間枠：Baseline and 6 weeks
|
Serum arylesterase (ARE, kU/L) activity will be determined using spectrophotometric methods.
The change in ARE activity from baseline to 6 weeks will be evaluated.
|
Baseline and 6 weeks
|
|
Change in High-Sensitivity C-Reactive Protein (hs-CRP)
時間枠：Baseline and 6 weeks
|
Serum high-sensitivity C-reactive protein (hs-CRP, mg/L) concentration will be measured using standard laboratory methods.
The change in hs-CRP levels from baseline to 6 weeks will be evaluated.
|
Baseline and 6 weeks
|
|
Change in Interleukin-6 (IL-6)
時間枠：Baseline and 6 weeks
|
Serum interleukin-6 (IL-6, pg/mL) concentration will be measured using enzyme-linked immunosorbent assay methods.
The change in IL-6 levels from baseline to 6 weeks will be evaluated.
|
Baseline and 6 weeks
|
|
Change in Tumor Necrosis Factor-Alpha (TNF-α)
時間枠：Baseline and 6 weeks
|
Serum tumor necrosis factor-alpha (TNF-α, pg/mL) concentration will be measured using enzyme-linked immunosorbent assay methods.
The change in TNF-α levels from baseline to 6 weeks will be evaluated.
|
Baseline and 6 weeks
|
|
Change in Serum Potassium Concentration
時間枠：Baseline and 6 weeks
|
Serum potassium concentration (mmol/L) will be measured using standard biochemical methods.
The change in serum potassium levels from baseline to 6 weeks will be evaluated.
|
Baseline and 6 weeks
|
|
Change in Serum Calcium Concentration
時間枠：Baseline and 6 weeks
|
Serum calcium concentration (mg/dL) will be measured using standard biochemical methods.
The change in serum calcium levels from baseline to 6 weeks will be evaluated.
|
Baseline and 6 weeks
|
|
Change in N-Terminal Pro-B-Type Natriuretic Peptide (NT-proBNP)
時間枠：Baseline and 6 weeks
|
Serum N-terminal pro-B-type natriuretic peptide (NT-proBNP, pg/mL) concentration will be measured using immunoassay methods.
The change in NT-proBNP levels from baseline to 6 weeks will be evaluated.
|
Baseline and 6 weeks
|
|
Change in Left Ventricular Ejection Fraction (LVEF)
時間枠：Baseline and 6 weeks
|
Left ventricular ejection fraction (LVEF, %) will be assessed by transthoracic echocardiography.
The change in LVEF from baseline to 6 weeks will be evaluated.
|
Baseline and 6 weeks
|
協力者と研究者
ここでは、この調査に関係する人々や組織を見つけることができます。
捜査官
- 主任研究者：Şemsi Gül Yılmaz Kocaman, PhD、Karamanoğlu Mehmetbey University
出版物と役立つリンク
研究に関する情報を入力する責任者は、自発的にこれらの出版物を提供します。これらは、研究に関連するあらゆるものに関するものである可能性があります。
一般刊行物
- Chavarrias M, Carlos-Vivas J, Collado-Mateo D, Perez-Gomez J. Health Benefits of Indoor Cycling: A Systematic Review. Medicina (Kaunas). 2019 Aug 8;55(8):452. doi: 10.3390/medicina55080452.
- Tarsitano MG, Quinzi F, Folino K, Greco F, Oranges FP, Cerulli C, Emerenziani GP. Effects of magnesium supplementation on muscle soreness in different type of physical activities: a systematic review. J Transl Med. 2024 Jul 5;22(1):629. doi: 10.1186/s12967-024-05434-x.
- Sireno L, Dimauro I, Caporossi D. Reactive oxygen species in exercise biology: from adaptive stress response to cell signaling and beyond. Free Radic Biol Med. 2026 Mar 1;245:447-462. doi: 10.1016/j.freeradbiomed.2025.12.044. Epub 2026 Jan 2. No abstract available.
- Reno AM, Green M, Killen LG, O'Neal EK, Pritchett K, Hanson Z. Effects of Magnesium Supplementation on Muscle Soreness and Performance. J Strength Cond Res. 2022 Aug 1;36(8):2198-2203. doi: 10.1519/JSC.0000000000003827. Epub 2020 Oct 1.
- Feng W, Wang Y, Gu X, Yu D, Liu Z. Exercise as a modulator of systemic inflammation and oxidative stress biomarkers across clinical and healthy populations: an umbrella meta-analysis. BMC Sports Sci Med Rehabil. 2025 Nov 28;17(1):360. doi: 10.1186/s13102-025-01327-8.
- Dominguez LJ, Veronese N, Ragusa FS, Baio SM, Sgro F, Russo A, Battaglia G, Bianco A, Barbagallo M. The Importance of Vitamin D and Magnesium in Athletes. Nutrients. 2025 May 13;17(10):1655. doi: 10.3390/nu17101655.
- Battista RA, Foster C, Andrew J, Wright G, Lucia A, Porcari JP. Physiologic responses during indoor cycling. J Strength Cond Res. 2008 Jul;22(4):1236-41. doi: 10.1519/JSC.0b013e318173dbc4.
研究記録日
これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。
主要日程の研究
研究開始 (実際)
2026年6月1日
一次修了 (推定)
2026年8月15日
研究の完了 (推定)
2026年8月20日
試験登録日
最初に提出
2026年6月5日
QC基準を満たした最初の提出物
2026年6月17日
最初の投稿 (実際)
2026年6月23日
学習記録の更新
投稿された最後の更新 (実際)
2026年6月23日
QC基準を満たした最後の更新が送信されました
2026年6月17日
最終確認日
2026年6月1日
詳しくは
本研究に関する用語
追加の関連 MeSH 用語
その他の研究ID番号
- 02-2026/29
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
いいえ
IPD プランの説明
Individual participant data will not be shared because the dataset contains participant-level health and performance records.
All results will be reported in aggregate form, and confidentiality will be maintained in accordance with applicable data protection regulations.
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
いいえ
米国FDA規制機器製品の研究
いいえ
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。